| New from NCI |
| Predictor for Immunotherapy Response |
 |
|
Read about research that may help predict which patients with melanoma are likely to respond to treatment with immune checkpoint inhibitors. |
| Ribociclib Approval Expanded |
 |
|
The Food and Drug Administration (FDA) has expanded the approved uses of ribociclib (Kisqali) for some women with advanced breast cancer. It’s the first approval under a new FDA program to speed the review of cancer drugs. |
Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer
A new study has found that 90% of women diagnosed with endometrial cancer after menopause reported vaginal bleeding before their diagnosis. Learn more about endometrial cancer and the study that led to these findings. |
NCI Director Reflects on the Life of Senator John McCain
Upon the passing of Senator John McCain, Dr. Norman Sharpless recalls the Senator’s years of service and long-time support for cancer research. |
| PDQ Summary Updates |
Breast Cancer Prevention
We've added information to our PDQ breast cancer prevention summary about studies that looked at whether hormonal birth control use affects a woman's risk of breast cancer. |
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment
We’ve revised our PDQ summary on ovarian cancer with updated information on treatment options for advanced disease. |
| Drug Information Updates |
Iobenguane I 131
We've added a new drug summary for iobenguane I 131 (Azedra). It was recently approved by FDA for certain patients with pheochromocytoma or paraganglioma that is locally advanced, has spread to other parts of the body, or cannot be removed by surgery. This is the first drug approved by FDA for this use. |
Lenvatinib Mesylate
We’ve updated our drug summary on lenvatinib mesylate (Lenvima) with a recent FDA approval. The drug is now approved as first-line therapy for patients with hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. |
